샘플 요청 목록

 카트 문의
시장보고서
상품코드
1757799

비강 백신 시장

Nasal Vaccines
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 220 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

비강 백신 세계 시장은 2030년까지 6억 6,530만 달러에 이를 전망

2024년에 4억 3,940만 달러로 추정되는 비강 백신 세계 시장은 2024-2030년 분석 기간에 CAGR 7.2%로 성장하여 2030년에는 6억 6,530만 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 약독화 생백신은 CAGR 9.3%를 나타내고, 분석 기간 종료시에는 1억 9,050만 달러에 이를 것으로 예측됩니다. 불활화 백신 분야의 성장률은 분석 기간 중 CAGR 8.8%로 추정됩니다.

미국 시장은 1억 1,970만 달러로 추정, 중국은 CAGR 11.5%로 성장 예측

미국의 비강 백신 시장은 2024년에 1억 1,970만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 1억 4,210만 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 11.5%로 추정됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 3.4%와 7.0%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 4.7%를 보일 전망입니다.

세계의 비강 백신 시장 - 주요 동향과 촉진요인 정리

왜 비강 백신은 예방접종 전략에서 추진력을 얻고 있는가?

비강 백신은 자연 감염 경로를 모방한 비침습적 점막 기반 예방접종을 제공함으로써 백신 전달 시스템의 혁신적인 발전으로 점점 더 인정받고 있습니다. 전신 면역을 자극하는 주사 백신과 달리 비강 백신은 많은 호흡기 병원체의 주요 침입 경로인 점막 표면을 표적으로 삼아 전신 면역과 국소 면역을 모두 유도합니다. 이 이중 반응은 예방 효과를 높일 뿐만 아니라 바이러스 배출과 감염을 감소시킬 수 있어 비강 백신은 전염병이 유행할 때 특히 유용합니다.

특히 어린이와 주사기 공포증이 있는 사람들에게 쉽게 투여할 수 있기 때문에 집단 예방접종 물류가 재구성되고 있습니다. 비강주사제는 훈련된 인력이나 주사기가 필요하지 않기 때문에 자원이 부족한 환경에서 배포를 간소화할 수 있습니다. 이러한 특성으로 인해 특히 신속하고 대규모 예방접종이 중요한 독감, 코로나19, 호흡기세포융합바이러스(RSV)와 같은 질병에 대한 전 세계의 관심이 높아지고 있습니다. 자가 투여의 가능성과 주사바늘로 인한 생물학적 유해 폐기물을 제거할 수 있다는 점은 이 플랫폼의 공중보건적 가치를 더욱 강조하고 있습니다.

비강 백신의 효과와 안정성을 향상시키는 과학적 진보는 무엇인가?

제형 과학과 전달 기술의 큰 혁신이 비강 백신 개발을 촉진하고 있습니다. 주요 발전 중 하나는 비강 내 항원 보유를 강화하여 더 강하고 오래 지속되는 면역 반응을 가져오는 새로운 보조제와 점착성 캐리어의 사용입니다. 리포좀, 나노 에멀젼, 폴리머 기반 전달 시스템은 항원이 분해되지 않도록 보호하는 동시에 점막 면역의 유도 부위인 비강 관련 림프 조직(NALT)에 의한 흡수를 촉진하도록 설계되었습니다.

내열성은 또 다른 발전 분야로, 연구원들은 콜드체인 물류의 필요성을 피하고 상온에서 보관할 수 있는 건조 분말을 개발하고 있습니다. 이 특성은 외딴 지역이나 인구가 적은 지역에서의 배포에 특히 중요합니다. 또한, 재조합 단백질 서브유닛과 바이러스 벡터는 비강투여용으로 조정되고 있으며, 보다 광범위한 항원 발현 프로파일과 다중 표적화를 제공합니다. 이러한 발전으로 인해 비강용 백신은 더욱 견고하고 다재다능하며 다양한 병원균에 대응할 수 있게 되었습니다.

최종 용도 및 공중 보건 전략은 어떻게 확장되고 있는가?

비강 백신의 최종 용도는 빠르게 진화하고 있으며, 국가 예방 접종 일정, 학교 기반 백신 프로그램 및 전염병 대응 전략에 통합되고 있습니다. 어린이와 노인은 호흡기 질환에 걸리기 쉽고 주사바늘을 통한 예방접종이 어렵기 때문에 중요한 타겟 그룹이 되고 있습니다. 또한, 비강 백신은 정맥주사 없이도 접종할 수 있기 때문에 응급상황이나 전염병 발생 시 현장에서 사용하기에 매우 적합합니다.

감염성 질환뿐만 아니라 알레르기, 알츠하이머병, 암 면역요법 등 비감염성 질환에 대한 응용도 연구되고 있습니다. 코에서 후각을 통해 중추신경계로 직접 접근할 수 있는 비강경로는 신경학적 및 전신 면역 조절을 위한 매력적인 관문입니다. 정부 및 민간 기업과의 협력은 의료 솔루션뿐만 아니라 백신의 수용성을 높이고, 의료 시스템의 부담을 줄이고, 발병에 대한 대응을 가속화하기 위한 전략적 도구로서 비강 면역에 대한 연구를 점점 더 많이 진행하고 있습니다.

비강 백신 시장의 성장을 가속하는 요인은 무엇인가?

비강 백신 시장의 성장은 전달 플랫폼의 발전, 대상 질환 프로파일의 확대, 예방접종 인프라의 시스템 변화와 관련된 여러 요인에 의해 주도되고 있습니다. 특히, 소아, 노인, 주사바늘을 싫어하는 사람들 사이에서 환자의 순응도를 높일 수 있는 주사바늘 없는 백신 옵션에 대한 수요가 증가하고 있는 것이 주요 요인 중 하나입니다. 이러한 수요는 접종이 용이하고 최소한의 훈련이 필요하며, 물류의 복잡성을 줄일 수 있는 집단 예방접종 현장에서 더욱 증가하고 있습니다.

공중보건, 여행 의료, 소아 의료, 응급상황 대응 등 다양한 최종 용도가 비강 백신의 상업적 잠재력을 확대시키고 있습니다. 전 세계적으로 호흡기 질환의 발병률 증가와 팬데믹 위협에 대한 대응책이 신속하고 확장 가능하며 비침습적인 백신 전달 솔루션에 대한 수요를 촉진하고 있습니다. 또한, 차세대 백신 플랫폼에 초점을 맞춘 규제 당국의 지원책과 자금 지원 이니셔티브가 R&D 투자를 촉진하고 임상시험을 가속화하고 있습니다.

제형 안정성, 콜드체인 비의존성, 다항원성과 같은 기술적 개선도 비강 백신의 가치 제안을 향상시키고 있습니다. 이러한 특성은 기존 주사용 백신이 물류적 어려움에 직면한 저자원 환경과 세계 백신 접종 계획에 특히 매력적인 요소로 작용하고 있습니다. 헬스케어, 생명공학, 국제 보건 정책 이해관계자들이 점막 면역의 이점을 공유함에 따라 비강 백신 시장은 강력한 성장과 공중보건에 큰 영향을 미칠 준비가 되어 있습니다.

부문

백신 유형(약독화 생백신, 불활화 백신, 아단위 백신, 유전자 재조합 백신, 혼합 백신, 기타 백신 유형);판매채널(공공, 민간)

조사 대상 기업 예(총 48개사)

  • Altimmune, Inc.
  • AstraZeneca
  • Bharat Biotech
  • BioDiem Ltd
  • BioNTech SE
  • BlueWillow Biologics
  • Changchun BCHT Biotechnology Co.
  • Codagenix Inc.
  • CyanVac LLC
  • FluGen Inc.
  • Gamma Vaccines Pty Ltd.
  • GlaxoSmithKline plc
  • Intravacc
  • Meissa Vaccines Inc.
  • Ocugen, Inc.
  • Pfizer Inc.
  • Razi Vaccine and Serum Research Institute
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Vaxart, Inc.

AI 통합

우리는 유효한 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM이나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.07.03

Global Nasal Vaccines Market to Reach US$665.3 Million by 2030

The global market for Nasal Vaccines estimated at US$439.4 Million in the year 2024, is expected to reach US$665.3 Million by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Live Attenuated Vaccines, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$190.5 Million by the end of the analysis period. Growth in the Inactivated Vaccines segment is estimated at 8.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$119.7 Million While China is Forecast to Grow at 11.5% CAGR

The Nasal Vaccines market in the U.S. is estimated at US$119.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$142.1 Million by the year 2030 trailing a CAGR of 11.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 7.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global Nasal Vaccines Market - Key Trends & Drivers Summarized

Why Are Nasal Vaccines Gaining Momentum in Immunization Strategies?

Nasal vaccines are increasingly recognized as a transformative advancement in vaccine delivery systems, offering needle-free, mucosal-based immunization that mimics natural infection pathways. Unlike injectable vaccines that stimulate systemic immunity, nasal vaccines target the mucosal surfaces-the primary entry points for many respiratory pathogens-thereby inducing both systemic and local immunity. This dual response not only improves protective efficacy but also reduces viral shedding and transmission, making nasal vaccines especially valuable during infectious disease outbreaks.

Their ease of administration, particularly in pediatric and needle-phobic populations, is reshaping mass vaccination logistics. Nasal sprays do not require trained personnel or syringes, simplifying distribution in low-resource settings. These features are driving increasing global interest, especially for diseases like influenza, COVID-19, and respiratory syncytial virus (RSV), where rapid, large-scale immunization is often critical. The potential for self-administration and the elimination of biohazardous waste associated with needles further underscore the public health value of this platform.

What Scientific Advances Are Enhancing the Efficacy and Stability of Nasal Vaccines?

Significant innovations in formulation science and delivery technology are boosting the development of nasal vaccines. One major advancement is the use of novel adjuvants and mucoadhesive carriers that enhance antigen retention in the nasal cavity, leading to stronger and longer-lasting immune responses. Liposomes, nanoemulsions, and polymer-based delivery systems are being engineered to protect antigens from degradation while promoting uptake by nasal-associated lymphoid tissue (NALT), the immune inductive site for mucosal immunity.

Thermostability is another area of progress, with researchers developing dry powder nasal vaccines that can be stored at ambient temperatures, bypassing the need for cold-chain logistics. This attribute is especially crucial for deployment in remote or underdeveloped regions. Additionally, recombinant protein subunits and viral vectors are being tailored for intranasal use, offering broader antigen expression profiles and multivalent targeting. Collectively, these advancements are making nasal vaccines more robust, versatile, and compatible with a wider range of pathogens.

How Are End-Use Applications and Public Health Strategies Expanding?

The end-use landscape for nasal vaccines is evolving rapidly, with increasing integration into national immunization schedules, school-based vaccine programs, and pandemic preparedness strategies. Pediatric and geriatric populations are emerging as key target groups due to their high susceptibility to respiratory diseases and the challenges they often face with needle-based vaccinations. Moreover, the ability to administer nasal vaccines without the need for intravenous access makes them highly suitable for use during emergencies and outbreaks in field conditions.

In addition to infectious diseases, research is expanding into nasal vaccines for non-communicable applications such as allergies, Alzheimer’s disease, and cancer immunotherapy. The nasal route provides direct access to the central nervous system via the olfactory bulb, making it an attractive portal for neurological and systemic immune modulation. Government and private-sector collaborations are increasingly exploring nasal immunization not only as a medical solution but as a strategic tool for boosting vaccine acceptance, reducing healthcare system burden, and accelerating outbreak response.

What Factors Are Driving Growth in the Nasal Vaccines Market?

The growth in the nasal vaccines market is driven by several factors tied to advancements in delivery platforms, expansion in target disease profiles, and systemic shifts in immunization infrastructure. One of the primary drivers is the rising demand for needle-free vaccine options that improve patient compliance, particularly among children, the elderly, and needle-averse individuals. This demand is further amplified in mass immunization settings where ease of administration and minimal training requirements reduce logistical complexity.

End-use diversification across public health, travel medicine, pediatric care, and emergency outbreak response is expanding the commercial viability of nasal vaccines. The increased incidence of respiratory illnesses and global preparedness efforts against pandemic threats are driving demand for rapid, scalable, and non-invasive vaccine delivery solutions. Additionally, supportive regulatory pathways and funding initiatives focused on next-generation vaccine platforms are catalyzing R&D investments and accelerating clinical trials.

Technological improvements in formulation stability, cold-chain independence, and multi-antigenic capability are also enhancing the value proposition of nasal vaccines. These attributes are making them particularly attractive for low-resource settings and global vaccination initiatives where traditional injectable vaccines face logistical challenges. As stakeholders across healthcare, biotechnology, and global health policy align around the benefits of mucosal immunization, the nasal vaccines market is poised for robust growth and significant public health impact.

SCOPE OF STUDY:

The report analyzes the Nasal Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines, Other Vaccine Types); Distribution Channel (Public, Private)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Altimmune, Inc.
  • AstraZeneca
  • Bharat Biotech
  • BioDiem Ltd
  • BioNTech SE
  • BlueWillow Biologics
  • Changchun BCHT Biotechnology Co.
  • Codagenix Inc.
  • CyanVac LLC
  • FluGen Inc.
  • Gamma Vaccines Pty Ltd.
  • GlaxoSmithKline plc
  • Intravacc
  • Meissa Vaccines Inc.
  • Ocugen, Inc.
  • Pfizer Inc.
  • Razi Vaccine and Serum Research Institute
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Vaxart, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Nasal Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Interest in Mucosal Immunity Drives Research and Adoption of Intranasal Vaccine Platforms
    • OEM Development of Needle-Free Delivery Systems Supports Vaccine Acceptance in Pediatric and Geriatric Populations
    • Growth in Respiratory Disease Prevalence, Including COVID-19 and Influenza, Strengthens Use of Nasal Vaccines
    • Push for Self-Administered Vaccine Formats Enhances Market for Nasal Spray Formulations
    • Increasing Demand for Cold Chain-Free and Room Temperature-Stable Vaccines Promotes Innovation in Nasal Delivery
    • OEM Focus on Adjuvant Optimization and Mucoadhesive Formulations Improves Efficacy of Nasal Vaccines
    • Expansion of Nasal Vaccine Clinical Trials Across Infectious Diseases and Allergies Broadens Market Pipeline
    • Rising Government and NGO Investment in Pandemic Preparedness Supports Nasal Vaccine Infrastructure
    • Integration of Nasal Delivery With mRNA and Recombinant Platforms Fuels Next-Gen Vaccine Development
    • Global Vaccination Campaigns in Low-Income Regions Drive Demand for Easy-to-Use, Non-Invasive Formats
    • Push for Mass Immunization Tools That Reduce Needle Waste Supports Nasal Route Innovation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Nasal Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Nasal Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Nasal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Live Attenuated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Live Attenuated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Inactivated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Inactivated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Subunit by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Subunit by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Recombinant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Recombinant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Conjugate Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Conjugate Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Other Vaccine Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Public by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Public by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Private by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Private by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • CANADA
    • TABLE 24: Canada Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Canada 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • JAPAN
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 28: Japan Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Japan 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 30: Japan Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Japan 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • CHINA
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: China 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 34: China Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: China 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • EUROPE
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 36: Europe Recent Past, Current & Future Analysis for Nasal Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 37: Europe 6-Year Perspective for Nasal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Europe 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 40: Europe Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Europe 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • FRANCE
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 42: France Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: France 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 44: France Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: France 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • GERMANY
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 46: Germany Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Germany 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 48: Germany Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Germany 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • ITALY
    • TABLE 50: Italy Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Italy 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 52: Italy Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Italy 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • UNITED KINGDOM
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 54: UK Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: UK 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 56: UK Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: UK 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • SPAIN
    • TABLE 58: Spain Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Spain 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 60: Spain Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Spain 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • RUSSIA
    • TABLE 62: Russia Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Russia 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 64: Russia Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Russia 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 66: Rest of Europe Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Rest of Europe 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 68: Rest of Europe Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Rest of Europe 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 70: Asia-Pacific Recent Past, Current & Future Analysis for Nasal Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 71: Asia-Pacific 6-Year Perspective for Nasal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
    • TABLE 72: Asia-Pacific Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Asia-Pacific 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 74: Asia-Pacific Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Asia-Pacific 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • AUSTRALIA
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 76: Australia Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Australia 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 78: Australia Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Australia 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • INDIA
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 80: India Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: India 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 82: India Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: India 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • SOUTH KOREA
    • TABLE 84: South Korea Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: South Korea 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 86: South Korea Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: South Korea 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 88: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Asia-Pacific 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 90: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of Asia-Pacific 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • LATIN AMERICA
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 92: Latin America Recent Past, Current & Future Analysis for Nasal Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 93: Latin America 6-Year Perspective for Nasal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
    • TABLE 94: Latin America Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Latin America 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 96: Latin America Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Latin America 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • ARGENTINA
    • TABLE 98: Argentina Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Argentina 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 100: Argentina Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Argentina 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • BRAZIL
    • TABLE 102: Brazil Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Brazil 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 104: Brazil Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Brazil 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • MEXICO
    • TABLE 106: Mexico Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Mexico 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 108: Mexico Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Mexico 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 110: Rest of Latin America Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Latin America 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 112: Rest of Latin America Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Rest of Latin America 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • MIDDLE EAST
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 114: Middle East Recent Past, Current & Future Analysis for Nasal Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 115: Middle East 6-Year Perspective for Nasal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
    • TABLE 116: Middle East Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Middle East 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 118: Middle East Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Middle East 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • IRAN
    • TABLE 120: Iran Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Iran 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 122: Iran Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Iran 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • ISRAEL
    • TABLE 124: Israel Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Israel 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 126: Israel Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Israel 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • SAUDI ARABIA
    • TABLE 128: Saudi Arabia Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Saudi Arabia 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 130: Saudi Arabia Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Saudi Arabia 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 132: UAE Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 133: UAE 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 134: UAE Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: UAE 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 136: Rest of Middle East Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Rest of Middle East 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 138: Rest of Middle East Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Rest of Middle East 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030
  • AFRICA
    • Nasal Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 140: Africa Recent Past, Current & Future Analysis for Nasal Vaccines by Vaccine Type - Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Africa 6-Year Perspective for Nasal Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Conjugate Vaccines and Other Vaccine Types for the Years 2025 & 2030
    • TABLE 142: Africa Recent Past, Current & Future Analysis for Nasal Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 143: Africa 6-Year Perspective for Nasal Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제